Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713574 | 0.92 | CCR5 (0.42) | CCR5CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL21164434 | 0.91 | PSIP1 (0.44) | CCR5CYP2C9CYP2C19CYP1A2NR1I2 | |
| SCHEMBL20372757 | 0.84 | CCR5 (0.41) | CCR5NR1I2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL20032390 | 0.83 | CCR5 (0.40) | CCR5CYP2C9CYP2C19CYP1A2NR1I2 | |
| SCHEMBL21164504 | 0.83 | CA2 (0.50) | CCR5CA1CA2 | |
| SCHEMBL17411225 | 0.81 | NR1I2 (0.42) | NR1I2SMN1; SMN2CA1CA2 | |
| SCHEMBL21470932 | 0.81 | KAT6A (0.40) | CYP2C9CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21164370 | 0.81 | TNNI3K (0.41) | CCR5NR1I2SMN1; SMN2CA1CA2 | |
| SCHEMBL18713459 | 0.80 | PSIP1 (0.50) | CCR5CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL17367964 | 0.78 | DRD2 (0.42) | CCR5CYP3A4CYP2D6SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | CCR5 408/4885CYP2C9 196/4885CYP2C19 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.